Literature DB >> 19732735

Lymphoma: which chemotherapy protocol and why?

Ruthanne Chun1.   

Abstract

Lymphoma is the most common hematologic neoplasm of dogs. Although the order of drug administration and duration of the maintenance portion of the protocol vary considerably, most oncologists agree that a doxorubicin-based (eg, CHOP) combination chemotherapy protocol provides the longest period of disease control and overall survival. The use of a prolonged maintenance phase is no longer recommended, but consolidation therapy may prove to be of benefit. Further, combination of chemotherapy with half- or whole-body radiation therapy or even bone marrow transplant is advocated by some institutions. The goal of this article is to summarize the current literature regarding chemotherapy for dogs with high-grade lymphoma and provide recommendations for therapy in a variety of different scenarios.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19732735     DOI: 10.1053/j.tcam.2009.03.003

Source DB:  PubMed          Journal:  Top Companion Anim Med        ISSN: 1946-9837


  9 in total

1.  Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma.

Authors:  Alessandra Gavazza; George Lubas; Arthur Fridman; Daniela Peruzzi; Joseph A Impellizeri; Laura Luberto; Emanuele Marra; Giuseppe Roscilli; Gennaro Ciliberto; Luigi Aurisicchio
Journal:  Hum Gene Ther       Date:  2013-08       Impact factor: 5.695

2.  Anthracycline-induced cardiomyopathy in a dog treated with epirubicin.

Authors:  Ye-Rin Lee; Min-Hee Kang; Hee-Myung Park
Journal:  Can Vet J       Date:  2015-06       Impact factor: 1.008

3.  Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential.

Authors:  Daisuke Ito; Susan Brewer; Jaime F Modiano; Melissa J Beall
Journal:  Leuk Lymphoma       Date:  2014-06-16

4.  Use of a depot steroid formulation with CHOP-based protocol in the treatment of mediastinal lymphoma in cats.

Authors:  J C Cartagena Albertus; J Engel Manchado; A Romairone Duarte; A Moise; S Moya Garcia; D Jones; J A Montoya-Alonso
Journal:  Iran J Vet Res       Date:  2018       Impact factor: 1.376

5.  Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3+ T cells in canine B cell lymphoma.

Authors:  Dammy Pinheiro; Yu-Mei Chang; Hannah Bryant; Balazs Szladovits; Tim Dalessandri; Lucy J Davison; Elizabeth Yallop; Emily Mills; Chiara Leo; Ana Lara; Anneliese Stell; Gerry Polton; Oliver A Garden
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

6.  A double blinded, placebo-controlled pilot study to examine reduction of CD34 +/CD117 +/CD133 + lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma.

Authors:  Daisuke Ito; Michael Childress; Nicola Mason; Amber Winter; Timothy O'Brien; Michael Henson; Antonella Borgatti; Mitzi Lewellen; Erika Krick; Jane Stewart; Sarah Lahrman; Bartek Rajwa; Milcah C Scott; Davis Seelig; Joseph Koopmeiners; Stephan Ruetz; Jaime Modiano
Journal:  F1000Res       Date:  2015-02-11

7.  Metabolic Abnormalities Detected in Phase II Evaluation of Doxycycline in Dogs with Multicentric B-Cell Lymphoma.

Authors:  Kelly R Hume; Skylar R Sylvester; Lucia Borlle; Cheryl E Balkman; Angela L McCleary-Wheeler; Mary Pulvino; Carla Casulo; Jiyong Zhao
Journal:  Front Vet Sci       Date:  2018-02-26

8.  MHCII Expression on Peripheral Blood Monocytes in Canine Lymphoma: An Impact of Glucocorticoids.

Authors:  Alicja Rzepecka; Dariusz Jagielski; Anna Cywińska; Rafał Sapierzyński; Magdalena Żmigrodzka; Olga Witkowska-Piłaszewicz; Anna Winnicka
Journal:  Animals (Basel)       Date:  2022-08-19       Impact factor: 3.231

Review 9.  Epigenetic Mechanisms in Canine Cancer.

Authors:  Pedro Luiz Porfirio Xavier; Susanne Müller; Heidge Fukumasu
Journal:  Front Oncol       Date:  2020-10-23       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.